You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

KAYEXALATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Kayexalate patents expire, and what generic alternatives are available?

Kayexalate is a drug marketed by Concordia and is included in one NDA.

The generic ingredient in KAYEXALATE is sodium polystyrene sulfonate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Kayexalate

A generic version of KAYEXALATE was approved as sodium polystyrene sulfonate by CMP PHARMA INC on January 19th, 1989.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for KAYEXALATE?
  • What are the global sales for KAYEXALATE?
  • What is Average Wholesale Price for KAYEXALATE?
Summary for KAYEXALATE
Drug patent expirations by year for KAYEXALATE
Drug Prices for KAYEXALATE

See drug prices for KAYEXALATE

Recent Clinical Trials for KAYEXALATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, IrvinePhase 4
Université de MontréalPhase 4
Nephrology Research Axis of Maisonneuve Rosemont HospitalPhase 4

See all KAYEXALATE clinical trials

US Patents and Regulatory Information for KAYEXALATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia KAYEXALATE sodium polystyrene sulfonate POWDER;ORAL, RECTAL 011287-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.